A randomized controlled trial of two different regimen in the treatment of unfavourable vaginjal bleeding in women on etonogestrel implant

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202508557960619

Enrollment

Registered

2025-08-04

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

management of menstrual side-effects following use of subdermal contraceptive implants

Interventions

combined oral contraceptives

mifepristone and doxycycline

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Clients who have been on Etonogestrel subdermal implant with complaints of menstrual irregularities; prolonged or frequent bleeding.

Exclusion criteria

Exclusion criteria: Pregnancy History of; •Venous thromboembolism, •Stroke, •Uncontrolled hypertension, •Coagulation disorder •Gynaecological cancer Known hypersensitivity to study drugs Current treatment with enzyme inducing drugs like phenytoin, carbamazepine, phenobarbital

Design outcomes

Primary

Measure	Time frame
mean number of days to cessation of bleeding	—

Secondary

Measure	Time frame
proportion of women who stopped bleeding within one week of initiation of medications, side-effects profile	—

Countries

Nigeria

Contacts

Public Contactteju ajayi

senior registrar. dept of obstetrIcs and gynaecology UBTH

tejualice@gmail.com08060191621

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026